Immunocore Holdings (IMCR) Gross Profit (2021 - 2026)

Immunocore Holdings (IMCR) has reported Gross Profit for 6 consecutive years, with $106.2 million the latest figure, recorded in Q1 2026.

• Quarterly Gross Profit rose 14.18% year-over-year to $106.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.1 million (up 23.57% YoY) and the FY2025 annual result came in at $394.9 million, up 28.44% from the prior year.
• Gross Profit rose to $106.2 million in Q1 2026 per IMCR's latest filing, from $101.8 million in the prior quarter.
• Over the last five years, Gross Profit for IMCR reached as high as $106.2 million in Q1 2026 and fell as low as $40.0 million in Q2 2022.
• A 5-year average of $75.1 million and a median of $72.0 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2022 — Gross Profit surged 532.86% — and 2026, when it increased 14.18%.
• Year by year, Gross Profit stood at $56.2 million in 2022, then increased by 24.39% to $70.0 million in 2023, then climbed by 19.67% to $83.7 million in 2024, then advanced by 21.56% to $101.8 million in 2025, then grew by 4.39% to $106.2 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $106.2 million, $101.8 million, and $103.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.